Guidance looks low and consensus high

2024e forecasts unchanged, '25e-'26e up by 1-2%. Q1 was a good start to a busy year. HOLD, TP of DKK 1,000.

A good start to the year

Q1 EPS 7% above, but some special elements. Backlog implies revenue estimates are robust. Strong momentum, high expectations - HOLD.

Growth slightly ahead but lack of upgrade likely to disappoint

Yard response and dry bulk qualms

Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.

Europris ASA: 1 director

A director at Europris ASA bought 7,232 shares at 68.704NOK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

SpareBank 1 Helgeland (Hold, TP: NOK134.00) - Turn in NII momentum

Helped by strong trading income, HELG reported a Q1 ROE of ~12% versus its >11% target, despite the pre-announced elevated loan losses. With one less interest day and margin pressure, ‘real NII’ fell 2.2% QOQ. While down QOQ, the CET1 ratio remained solid at 18.1% (>16.5% target). We have cut our 2025–2026e EPS by ~3–5%, driven by lower NII, and lowered our target price to NOK134 (139). Trading at a 2025e P/E of ~9.0x, we continue to find a more attractive risk/reward elsewhere in the sector and...

ALK-Abello (Buy, TP: DKK145.00) - Set for still-strong European tablet...

We expect another strong quarter for European tablet sales in Q1, up c15% YOY, marking a third consecutive quarter with growth in the teens, which should help boost investor confidence (results due at 07:00 CET on 3 May). However, due to tough comparables for the legacy business and seasonality patterns, we expect the 2024 guidance to be maintained. We reiterate our BUY and have raised our target price to DKK145 (140).

Swedish Orphan Biovitrum (Buy, TP: SEK335.00) - Strong start to 2024

The Q1 earnings were above our forecast, even though some of the positive effects were one-offs (manufacturing revenues, among others). We believe Vonjo sales have bottomed out and we should be back at QOQ growth from Q2. The haemophilia franchise enjoyed stronger than expected growth, but some of this was due to phasing between quarters (hence this might hurt Q2 sales slightly). We reiterate our BUY and have increased our target price to SEK335 (320).

Q1 shows core SOBI sales model works

Strong Q1 numbers, 20% CER growth and 5-15% adj EBITA beat. Vonjo questions remain, but Q1 shows that SOBI sales model works. EPS +1-2% and unchanged BUY, as core case is reaffirmed.

SpareBank1 SR-Bank (Buy, TP: NOK158.00) - Solid growth and asset quali...

With NII remaining at high levels and modest loan losses, SRBNK reported a Q1 ROE of 14.6% versus its >13% target. Following strong lending growth of 2.3% QOQ, the CET1 ratio was flat QOQ, with the bank highlighting cNOK2.5bn synergy potential from the pending merger with SpareBank 1 Sørøst-Norge. We have made only minor changes to our 2025–2026e EPS. With the stock trading at a 2025e P/E of ~8.9x, we continue to find the valuation attractive. We reiterate our BUY and NOK158 target price.

Norwegian Air Shuttle (Buy, TP: NOK21.00) - Weak Q1 due to higher cost...

Norwegian Air Shuttle traded down c7% on Wednesday on weaker than expected Q1 results hit by higher costs, which made the market question the reiterated 2024 CASK guidance. We reiterate our BUY but have lowered our target price to NOK21 (23) on negative estimate revisions, reflecting slightly revised cost assumptions.

Europris (Buy, TP: NOK80.00) - Not its best report

Both the Q1 results and the 2024 cost guidance disappointed. However, we reiterate our BUY as we continue to find the valuation attractive and believe Europris has a winning concept in the current market, but have lowered our target price to NOK80 (85), reflecting our estimate cuts.

In need of a higher ROE

Adj. PTP +10% vs. ABGSCe (lower cost and loan losses). EPS up +6%, +5% and 6% for '24e/25e/26e. Valuation in line with fundamentals: HOLD.

Stora Enso (Buy, TP: EUR16.50) - On track

Due to better volumes and prices in the packaging materials division, underlying Q1 earnings were above our expectations. Looking ahead, earnings are set to be supported by higher pulp prices at the same time as pricing power has strengthened for most of Stora Enso’s packaging products. We have made limited changes to our 2024–2027 forecasts, but as we are increasingly confident that Stora Enso will be able to raise its profits to a sustainably healthy level, we have increased our target price t...

Up from a low base

ATH profits next

Weak Q1 in a seasonally small quarter, upbeat outlook kept. Unit costs need to improve - key for confidence. '24e EPS down 2.5%. BUY, TP NOK 21.

Feeling the pressure

Weak Q1, EBIT 27% below on higher costs. Being squeezed on many fronts – GM & costs. Market will improve, but a soft Q2 is likely: HOLD.

Europris (Buy, TP: NOK85.00) - Weak report and guidance

We consider this a weak report, below expectations due to lower gross margins and higher costs, and a cost guidance above expectations. We expect consensus 2024e EBITDA to come down 7.5–10% and believe a c5–10% negative share price reaction is warranted.

Q1'24: strong sales and decent margin

Stronger growth and better costs

Adj. PTP beat of 10% vs. ABGSCe, 2% vs cons. driven by lower loan losses and better costs as income just soft. Cons. EPS chg. likely down 1-3%, stock likely flat to -2% today